TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05209412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
Study: NCT05393817

Intervention type: DRUG
Intervention: caffeine citrate
Description: caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)

Intervention type: DRUG
Intervention: caffeine citrate
Description: caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
Study: NCT05850052

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional direct laryngoscopy using a Macintosh blade
Description: Examine a patient's airway to aid placement of tracheal tube with ease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope for rapid sequence endotracheal intubation
Description: Visualize a patient's airway to aid placement of tracheal tube with ease.
Study: NCT05993598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
Study: NCT04825015

Intervention type: DEVICE
Intervention: VEnaRt Cardiac Output
Description: Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
Study: NCT06318663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivor Mom Companion
Description: Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survivor Mom Companion
Description: Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
Study: NCT05332834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SM17
Description: Peripheral intravenous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peripheral intravenous injection
Study: NCT05631236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Therapy (AYO Glasses)
Description: Bright light glasses that emit a more intense therapeutic blue light.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bright Light Therapy (AYO Glasses)
Description: Bright light glasses that emit a non-therapeutic blue light.
Study: NCT04410575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pharmacist Care
Description: Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
Study: NCT05799443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
Study: NCT04616053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Description: A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist ...). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology ...) and/or collective care (for example : patient education, physical activity, relaxation ...). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
Study: NCT04410575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pharmacist Care
Description: Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reviewed Questionnaire tool results with participant
Description: Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Clinical Assessment
Description: Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy Referral
Description: Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist initiated interim telephone follow-up with participant
Description: Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication update with physician after participant contact
Description: Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Counselling and Educational Support
Description: Pharmacist provides medication related counselling and educational support to participant
Study: NCT05799443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
Study: NCT04410575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Counselling and Educational Support
Description: Pharmacist provides medication related counselling and educational support to participant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-medication Counselling
Description: Pharmacist provides non-medication related counselling and educational support to participant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-medication Counselling
Description: Pharmacist provides non-medication related counselling and educational support to participant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Identification of drug interaction
Description: Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identification of drug interaction
Description: Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Identification of drug adverse effect
Description: Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identification of drug adverse effect
Description: Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Identification of severe deterioration
Description: Pharmacist identification of participant severe deterioration (i.e. suicide attempt)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identification of severe deterioration
Description: Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
Study: NCT04846595

Intervention type: OTHER
Group type: OTHER
Intervention: self questionnaire
Description: Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
Study: NCT06465498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LUS decongestive strategy
Description: LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PE decongestive strategy
Description: PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
Study: NCT06291233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Interview Training (VIT)
Description: Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services-as-usual
Description: Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
Study: NCT05575869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (online) PRONEtect educational material
Description: This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic (normal) one hour lesson/lecture
Description: As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
Study: NCT05719038

Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: observational study

Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: observational study

Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: observational study
Study: NCT06131047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity Traditional Resistance Traning without Blood Flow Restriction
Description: Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity Traditional Resistance Traning with Blood Flow Restriction
Description: Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
Study: NCT05799443

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 8-10Gy×5F，QOD
Study: NCT04410575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing
Description: Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing
Description: Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing
Description: Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
Study: NCT06611592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.088mg/tid
Description: Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.18 mg/tid
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt).
Study: NCT05775250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: giomer varnish
Description: Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: giomer varnish
Description: Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
Study: NCT06043128

Intervention type: OTHER
Intervention: Patients With Stroke With Different Trunk Impact Levels
Description: Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form.

Intervention type: OTHER
Intervention: Patients With Stroke With Different Trunk Impact Levels
Description: Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form.
Study: NCT04991233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital craniotomy surgery
Description: The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
Study: NCT06254105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HANDY programme
Description: The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
Study: NCT05262270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Naltrexone
Description: XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
Study: NCT04542382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Inhibitor arm)
Description: Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet.
Study: NCT05262270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Buprenorphine
Description: Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
Study: NCT04542382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet.
Study: NCT05262270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Injectable matched to XR-NTX
Description: 3 doses of intramuscular injections (Week 0, 3, 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Injectable matched to XR-BUP
Description: 2 doses of subcutaneous injections (Week 0, 4)
Study: NCT04719065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.